Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 437 • 2015 ACR/ARHP Annual Meeting
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Tanja Schjødt Jørgensen¹, Carl Turesson², Meliha C. Kapetanovic³, Martin Englund^4,5, Aleksandra Turkiewicz⁴, Robin Christensen¹, Henning Bliddal¹, Pierre Geborek³ and Lars Erik Kristensen¹, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Little is known about the role of different mode…
Abstract Number: 1552 • 2015 ACR/ARHP Annual Meeting
Illness Perceptions in Rheumatoid Arthritis: A Comparison of Canadian and Nigerian Patients
Susan J. Bartlett¹, Olufemi Adelowo², Maria Celia Bazan Bardales³ and Ines Colmegna⁴, ¹Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Arthrimed Specialist Clinic, Lagos, Nigeria, ³Rheumatology, McGill University, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada
Background/Purpose: Illness perceptions (IP) are the beliefs and expectations that an individual has about medical conditions. IP cluster around five coherent themes and provide a…
Abstract Number: 2610 • 2015 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up
Boulos Haraoui¹, Shahin Jamal², Vandana Ahluwalia³, Tarang Manchanda⁴ and Majed M. Khraishi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Vancouver Coastal Health, Vancouver, BC, Canada, ³Brampton Civic Hospital, Brampton, ON, Canada, ⁴Hoffmann-La Roche Canada, Mississauga, ON, Canada, ⁵Nexus Clinical Research, St Johns, NF, Canada
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 1555 • 2015 ACR/ARHP Annual Meeting
Geography and the Influence of Comorbidity on the Prevalence of Depression in Patients with Rheumatoid Arthritis,a Study Across Seventeen Countries
Raluca Dumitru¹, Elizabeth M.A. Hensor², Ihsane Hmamouchi³, Paul Emery², Maxime Dougados⁴ and Maya H. Buch⁵, ¹University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³El Ayachi Hospital, Rabat, Morocco, ⁴Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Comorbidities represent a major challenge for patients with rheumatoid arthritis. Depression is one of the most common comorbidities with prevalence up to 38%. Disease…
Abstract Number: 2626 • 2015 ACR/ARHP Annual Meeting
Disease Activity Predicts ABCB1 and ABCG2 Drug-Efflux Transporters Function in Rheumatoid Arthritis (RA) Patients
Yemil Atisha-Fregoso¹, Guadualupe Lima², Virginia Pascual-Ramos³, Juan Jakez-Ocampo⁴, Hilda Fragoso-Loyo⁵, Miguel Baños⁶, Luis Llorente⁷ and Irazú Contreras-Yáñez⁸, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁵Vasco de Quiroga 15 Col Seccio, INNCMSZ-Departamento de Inmunología y Reumato, Mexico, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: ABCB1 (P-gp) and ABCG2 (BCRP1) are part of the adenine triphosphate (ATP)-binding cassette transporter proteins. These proteins can modulate inflammatory responses and mediate efflux…
Abstract Number: 2132 • 2014 ACR/ARHP Annual Meeting
What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity?
Violaine Foltz¹, Lisa Biale², Frederique Gandjbakhch¹, Laure Gossec¹, Pierre Bourgeois¹, Benjamin Granger³ and Bruno Fautrel¹, ¹Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France, ²Rheumatology, Instruction des Armées Begin hospital, Saint-mande, France, ³Departement de santé publique, information medicale et biostatistiques, unite biotstatistiques, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose Persistent inflammation on Power Doppler (PD) by ultrasound (US) was associated with relapse and structural progression after one year of follow up in a…
Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting
Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness
Kuljeet Bhamra¹, Catherine Swales¹, Matthew Seymour¹, Catherine McClinton¹ and Peter C. Taylor², ¹Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom
Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 124 • 2014 ACR/ARHP Annual Meeting
Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis
Jackie L. Nam, Laura Hunt, Elizabeth M.A. Hensor, Philip G. Conaghan, Richard J. Wakefield and Paul Emery, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose The use of musculoskeletal ultrasound is increasing in rheumatology practice. Recently we have shown that use of power Doppler signal (PD) on ultrasound in…
Abstract Number: 2030 • 2014 ACR/ARHP Annual Meeting
Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study
Mette Axelsen¹, Trine Bay Laurberg¹, Robin Christensen², Ulrich Fredberg³ and Torkell Ellingsen^4,5,6, ¹Silkeborg Hospital, Silkeborg, Denmark, ²Rheumatology, MSU, The Parker Institute, Copenhagen University Hospital, Frederiksberg, Denmark, ³Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁴Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁵The Danish National Registry DANBIO, Odense, Denmark, ⁶Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark
Background/Purpose Finding prognostic factors for treatment failure on synthetic disease modifying antirheumatic drugs (DMARD) in early treatment naive rheumatoid arthritis (RA) is a challenge. The…
Abstract Number: 1430 • 2014 ACR/ARHP Annual Meeting
IMPACT of Initiative to Control Cardiovascular Risk Factors in Collaboration with LOCAL Doctors in Patients with Rheumatoid Arthritis
Andrea Zacarias Crovato¹, Javier Narváez², Joan Miquel Nolla³, Jesús Rodríguez-Moreno⁴, Montserrat Jordana¹ and Carmen Gomez Vaquero³, ¹Hospital Universitari de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with cardiovascular risk (CVR) with an increased prevalence of cardiovascular events and cardiovascular mortality than the general population. Good…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 2936 • 2014 ACR/ARHP Annual Meeting
Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases, and How Does These Risks Compare to Those in Rheumatoid Arthritis?
Johan Askling¹, Lennart Jacobsson² and Jonas Eriksson¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²sahlrenska academy, gothenburg, Sweden
Background/Purpose Patients with RA are at increased risk of cardiovascular (CV) diseases, including acute coronary syndromes (ACS), deep venous thromboembolism (DVT) and pulmonary embolism (PE),…
Abstract Number: 2024 • 2014 ACR/ARHP Annual Meeting
Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study
Michel De Bandt¹, Rishika Banydeen², Lauren Brunier³, Katleen Polomat⁴, Veronique Dehlinger⁵, Serge Arfi⁴, Christophe Deligny⁴, Benedicte Garnery⁶, Helene Cormier⁷, Fabienne Dubreuil⁸, Patrick Numeric⁹, Danielle Dufrenot¹⁰, Sabine Molcard⁷, Loic Brithmer⁷, Olivier Fuhrer⁷, Lucien Louis-Joseph¹¹, Sylvie Merle² and Georges Jean-Baptiste⁵, ¹CHUM de Martinique, Unit of rheumatology, Fort de France, France, ²Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of epidemiology and biostatistics, Fort de FRance, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ⁴CHUM de Martinique,, unit of internal medicine, Fort de France, France, ⁵CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁶Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of internal medicine, Fort de France, France, ⁷Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de France, France, ⁸Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of rheumatology, Fort de FRance, France, ⁹route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ¹⁰Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fot de France, France, ¹¹Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de FRance, France
Background/Purpose Rheumatoid arthritis (RA) is a disabling chronic disease, regarded as the most frequent inflammatory rheumatism in adults, with a prevalence estimated between 0.3 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].